Form4insider filings, from the source

SEC Form 4 · accession 0001209191-15-049284

Phio Pharmaceuticals Corp. · PHIO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Geert Cauwenbergh
Officer — President & CEO · Director
Period of report
Jun 2, 2015
Accepted (ET)
Jun 3, 2015 · 8:02 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001533040

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common stock, $0.0001 par valueJun 2, 2015A70,000$0.40A137,500D
Common stock, $0.0001 par valueJun 2, 2015A10,000$0.40A15,000IBy spouse
Common stock, $0.0001 par valueF1holding———4,500IBy child

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Overallotment purchase right$0.455Jun 2, 2015A35,000AJun 2, 2015Jul 2, 2016Common stock35,00035,000D
Common stock warrant$0.52Jun 2, 2015A35,000AJun 2, 2015Jun 2, 2020Common stock35,00035,000D
Overallotment purchase right$0.455Jun 2, 2015A5,000AJun 2, 2015Jul 2, 2016Common stock5,0005,000I
Common stock warrant$0.52Jun 2, 2015A5,000AJun 2, 2015Jun 2, 2020Common stock5,0005,000I

Explanation of responses